Sector#Biotechnology - Therapeutics
- #Therapeutics - Drug delivery
- #Therapeutics - Peptides
- #Therapeutics - Proteins
- #Therapeutics - Antibodies
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Endocrine - nutritional and metabolic diseases
- #Neoplasms / cancer / oncology
- #Respiratory system
Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.
We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.
Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.
Upcoming eventsAll events
0712 '22Event by: VIB
1212 '22Event by: VIB
2911 '22Event by: Eurasanté
Latest newsMore news
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
14 hours ago
Indigo Diabetes announces first participant enrolled in the SHINE clinical trial
Thursday September 29th 2022
FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome
Tuesday September 27th 2022